Cargando…
Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib
IMPORTANCE: When a novel drug is granted accelerated approval, both its on-label and off-label uses must be taken into account. OBJECTIVES: To estimate the potential upper bound of off-label use of erdafitinib to treat advanced cancer with fibroblast growth factor receptor gene (FGFR) alterations, c...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Medical Association
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902826/ https://www.ncbi.nlm.nih.gov/pubmed/31755953 http://dx.doi.org/10.1001/jamanetworkopen.2019.16091 |